Acrux Future Growth

Future criteria checks 6/6

Acrux is forecast to grow earnings and revenue by 115.3% and 33.4% per annum respectively. EPS is expected to grow by 115.8% per annum. Return on equity is forecast to be 46% in 3 years.

Key information

115.3%

Earnings growth rate

115.8%

EPS growth rate

Pharmaceuticals earnings growth	26.3%
Revenue growth rate	33.4%
Future return on equity	46.0%
Analyst coverage	Low
Last updated	04 Mar 2024

Recent future growth updates

No updates

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

Earnings and Revenue Growth Forecasts

ASX:ACR - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	20	10	11	11	1
6/30/2025	12	2	3	3	1
6/30/2024	7	-4	-3	-3	1
12/31/2023	11	-1	0	1	N/A
9/30/2023	10	-1	0	1	N/A
6/30/2023	8	-1	1	1	N/A
3/31/2023	5	-4	-3	-3	N/A
12/31/2022	2	-8	-6	-6	N/A
9/30/2022	2	-9	-8	-7	N/A
6/30/2022	2	-10	-9	-9	N/A
3/31/2022	1	-10	-11	-10	N/A
12/31/2021	1	-10	-12	-12	N/A
9/30/2021	1	-11	-12	-11	N/A
6/30/2021	1	-13	-12	-11	N/A
3/31/2021	1	-12	-10	-10	N/A
12/31/2020	2	-11	-9	-9	N/A
9/30/2020	1	-10	-9	-9	N/A
6/30/2020	1	-9	-9	-9	N/A
3/31/2020	0	-10	-8	-8	N/A
12/31/2019	-1	-11	-8	-8	N/A
9/30/2019	0	-10	-9	-9	N/A
6/30/2019	1	-8	-10	-10	N/A
3/31/2019	2	-9	-10	-10	N/A
12/31/2018	3	-9	-10	-10	N/A
9/30/2018	3	-12	-8	-8	N/A
6/30/2018	3	-14	-6	-5	N/A
3/31/2018	8	-15	-2	-2	N/A
12/31/2017	12	-15	1	1	N/A
9/30/2017	18	-8	N/A	3	N/A
6/30/2017	24	0	N/A	5	N/A
3/31/2017	24	5	N/A	8	N/A
12/31/2016	25	10	N/A	11	N/A
9/30/2016	27	11	N/A	14	N/A
6/30/2016	29	13	N/A	17	N/A
3/31/2016	29	13	N/A	16	N/A
12/31/2015	29	14	N/A	16	N/A
9/30/2015	27	12	N/A	13	N/A
6/30/2015	25	11	N/A	11	N/A
3/31/2015	25	11	N/A	21	N/A
12/31/2014	24	10	N/A	32	N/A
9/30/2014	39	19	N/A	34	N/A
6/30/2014	54	28	N/A	36	N/A
3/31/2014	55	29	N/A	24	N/A
12/31/2013	55	30	N/A	12	N/A
9/30/2013	36	18	N/A	9	N/A
6/30/2013	17	7	N/A	6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: ACR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ACR is expected to become profitable in the next 3 years.

Revenue vs Market: ACR's revenue (33.4% per year) is forecast to grow faster than the Australian market (4.9% per year).

High Growth Revenue: ACR's revenue (33.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ACR's Return on Equity is forecast to be very high in 3 years time (46%).

Acrux Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Recent updates

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies